Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study June 2025 Congress News Read more
2023 May Clinical trials Gemtuzumab ozogamicin reduces the incidence of relapse in NPM1-mutated AML patients Read more
2023 May Pharma News FDA approves epcoritamab for the treatment of R/R diffuse large B-cell lymphoma Read more
2023 May Clinical trials Promising efficacy and safety results of nipocalimab in high-risk HDFN patients Read more
2023 May Clinical trials Immune effects of rituximab in children with high-risk B-cell non-Hodgkin lymphoma Read more
2023 April Clinical trials Balancing the benefits and risks of endovascular thrombectomy for large ischemic strokes Read more
2023 April Clinical trials Adding defibrotide to standard prophylaxis may help to prevent acute graft-versus-host disease Read more
Top
